{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T08:34:19Z","timestamp":1792917259420,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07648-7","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T07:59:22Z","timestamp":1763193562000},"page":"2478-2488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Normal organ [68Ga]DOTATOC uptake during PRRT: challenging the assumption of stable background shaped by cold somatostatin analogues treatment"],"prefix":"10.1007","volume":"53","author":[{"given":"Hind","family":"Ait Talhiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Baltzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Frega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Collen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Colin Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G.","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Porot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Ben","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-5146","authenticated-orcid":false,"given":"Alessio","family":"Imperiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"7648_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"7648_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","volume":"57","author":"CM Deroose","year":"2016","unstructured":"Deroose CM, Hindi\u00e9 E, Kebebew E, Pacak K, Ta\u00efeb D, Imperiale A. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949\u201356.","journal-title":"J Nucl Med"},{"key":"7648_CR3","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, et al. European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022;34:e13146.","journal-title":"J Neuroendocrinol"},{"key":"7648_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"7648_CR5","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic Well-Differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41:5049\u201367.","journal-title":"J Clin Oncol"},{"key":"7648_CR6","doi-asserted-by":"publisher","first-page":"e13479","DOI":"10.1111\/jne.13479","volume":"37","author":"V Prasad","year":"2025","unstructured":"Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, et al. Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European neuroendocrine tumor society advisory board meeting 2022 and the ENETS theranostics task force. J Neuroendocrinol. 2025;37:e13479.","journal-title":"J Neuroendocrinol"},{"key":"7648_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.semnuclmed.2025.04.005","volume":"55","author":"M Di Franco","year":"2025","unstructured":"Di Franco M, Lamberti G, Campana D, Ambrosini V. Molecular imaging for response assessment of neuroendocrine tumors (NET). Semin Nucl Med. 2025;55:754\u201365.","journal-title":"Semin Nucl Med"},{"key":"7648_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12020-024-04138-y","volume":"87","author":"D Mamulashvili Bessac","year":"2025","unstructured":"Mamulashvili Bessac D, Baltzinger P, Poterszman N, Pham Van F, Collen C, Malouf GG, et al. Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET\/CT in patients with metastatic small intestine neuroendocrine tumors. Endocrine. 2025;87:1333\u201341.","journal-title":"Endocrine"},{"key":"7648_CR9","first-page":"171","volume":"57","author":"FL Giesel","year":"2013","unstructured":"Giesel FL, Stefanova M, Schwartz LH, Afshar-Oromieh A, Eisenhut M, Haberkorn U, et al. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET\/CT uptake in normal tissue. Q J Nucl Med Mol Imaging. 2013;57:171\u20136.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"7648_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/RLU.0000000000004670","volume":"48","author":"D Morland","year":"2023","unstructured":"Morland D, Laures N, Triumbari EKA, Perrier M, Imperiale A, Annunziata S, Rufini V. Impact of cold somatostatin analog administration on somatostatin receptor imaging: A systematic review. Clin Nucl Med. 2023;48:467\u201373.","journal-title":"Clin Nucl Med"},{"key":"7648_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor-Based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343.","journal-title":"J Nucl Med"},{"key":"7648_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","volume":"22","author":"M Albertelli","year":"2021","unstructured":"Albertelli M, Dotto A, Di Dato C, Malandrino P, Modica R, Versari A, et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord. 2021;22:563\u201379.","journal-title":"Rev Endocr Metab Disord"},{"key":"7648_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, W\u00e4ngler B, Schmidt GP, Uebleis C, G\u00f6ke B, et al. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349\u201356.","journal-title":"J Nucl Med"},{"key":"7648_CR14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative 68Ga-DOTATATE PET\/CT parameters for prediction of therapy response and PFS in patients treated with 177Lu-DOTATATE. J Nucl Med. 2021;62:1406\u201314.","journal-title":"J Nucl Med"},{"key":"7648_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/cancers14030592","volume":"14","author":"R Durmo","year":"2022","unstructured":"Durmo R, Filice A, Fioroni F, Cervati V, Finocchiaro D, Coruzzi C, et al. Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET\/CT parameters in metastatic NET patients treated with PRRT. Cancers (Basel). 2022;14:592.","journal-title":"Cancers (Basel)"},{"key":"7648_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115\u201354.","journal-title":"Endocr Pathol"},{"key":"7648_CR17","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00259-024-06659-0","volume":"51","author":"T van de Weijer","year":"2024","unstructured":"van de Weijer T, Bemer F, de Vos-Geelen J, Hermans B, Mitea C, van der Pol JAJ, et al. Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment. Eur J Nucl Med Mol Imaging. 2024;51:2420\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7648_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2967\/jnumed.111.089276","volume":"52","author":"AR Haug","year":"2011","unstructured":"Haug AR, Rominger A, Mustafa M, Auernhammer C, G\u00f6ke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET\/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52:1679\u201383.","journal-title":"J Nucl Med"},{"issue":"10","key":"7648_CR19","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7648_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40644-018-0136-x","volume":"18","author":"MH Cherk","year":"2018","unstructured":"Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on 68Ga-DOTA-Octreotate PET\/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients May result in pseudoprogression. Cancer Imaging. 2018;18:3.","journal-title":"Cancer Imaging"},{"key":"7648_CR21","doi-asserted-by":"publisher","first-page":"e13423","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36:e13423.","journal-title":"J Neuroendocrinol"},{"key":"7648_CR22","doi-asserted-by":"publisher","first-page":"e05267","DOI":"10.1016\/j.heliyon.2020.e05267","volume":"6","author":"M Tamal","year":"2020","unstructured":"Tamal M. Intensity threshold based solid tumour segmentation method for positron emission tomography (PET) images: A review. Heliyon. 2020;6:e05267.","journal-title":"Heliyon"},{"key":"7648_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7648_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-018-1293-9","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, H\u00e4nscheid H, Leal JP, Javadi MS, Higuchi T, Lodge MA, et al. Impact of tumor burden on quantitative [68Ga]DOTATOC biodistribution. Mol Imaging Biol. 2019;21:575\u201384.","journal-title":"Mol Imaging Biol"},{"key":"7648_CR25","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/diagnostics11071216","volume":"11","author":"F G\u00fchne","year":"2021","unstructured":"G\u00fchne F, Heinzig A, Seifert P, Drescher R, Freesmeyer M. The dependence of renal 68Ga[Ga]-DOTATOC uptake on kidney function and its relevance for peptide receptor radionuclide therapy with 177Lu[Lu]-DOTATOC. Diagnostics (Basel). 2021;11:1216.","journal-title":"Diagnostics (Basel)"},{"key":"7648_CR26","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic Castration-resistant prostate cancer. Radiology. 2023;308:e222148.","journal-title":"Radiology"},{"key":"7648_CR27","first-page":"611","volume":"13","author":"F Dondi","year":"2023","unstructured":"Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R, et al. PET criteria by cancer type from imaging interpretation to treatment response assessment: beyond FDG PET score. Life (Basel). 2023;13:611.","journal-title":"Life (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07648-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:34Z","timestamp":1771479514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7648"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07648-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinky and was approved by local Institutional Review Board (Faculty of Medicine\/Strasbourg University Hospitals, CE-2024-135).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a02.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}